RhumbLine Advisers’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

RhumbLine Advisers’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125,890	Closed	-$2.35M	–	3339
2022 Q1	$2.35M	Buy	125,890 +9,633	+8%	+$173K	﹤0.01%	1728
2021 Q4	$2.49M	Buy	116,257 +10,786	+10%	+$213K	﹤0.01%	1758
2021 Q3	$1.95M	Buy	105,471 +15,429	+17%	+$311K	﹤0.01%	1921
2021 Q2	$1.93M	Sell	90,042 -5,079	-5%	-$103K	﹤0.01%	1970
2021 Q1	$1.83M	Buy	+95,121	New	+$1.68M	﹤0.01%	1959

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RhumbLine Advisers's OCDX Position: Q2 2022 in Review

RhumbLine Advisers sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 125,890 shares — an estimated $2.35M sold.

RhumbLine Advisers first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $2.49M in Q4 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

RhumbLine Advisers reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 125,890 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $2.35M.
RhumbLine Advisers first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
RhumbLine Advisers's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $2.49M in Q4 2021.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.